Dinesh de Alwis

Immunogenicity of pembrolizumab in patients with advanced tumors

Marianne J.H. van Vugt, Julie A. Stone, “Rik” H. J. M. M. De Greef et al. · Journal for ImmunoTherapy of Cancer · 2019 · 56 citations · Full text

Pharmacy, Oncology, Pharmacology +17

A six-weekly (Q6W) dosing schedule for pembrolizumab based on an exposure-response (E-R) evaluation using modeling and simulation.

Mallika Lala, Mengyao Li, Vikram Sinha et al. · Journal of Clinical Oncology · 2018 · 42 citations

Pharmacy, Pharmacokinetics, Pharmacology +15

Abstract CT042: Pembrolizumab 400 mg Q6W dosing: First clinical outcomes data from Keynote-555 cohort B in metastatic melanoma patients

Mallika Lala, Omobolaji O. Akala, Elliot Chartash et al. · Cancer Research · 2020 · 26 citations

Medicine, Oncology, Pharmacology +13

Population pharmacokinetics of letermovir following oral and intravenous administration in healthy participants and allogeneic hematopoietic cell transplantation recipients

Marita Prohn, Anders Viberg, Da‐Lin Zhang et al. · CPT Pharmacometrics & Systems Pharmacology · 2021 · 25 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +8

Getting Innovative Therapies Faster to Patients at the Right Dose: Impact of Quantitative Pharmacology Towards First Registration and Expanding Therapeutic Use

Satyaprakash Nayak, Oliver Sander, Nidal Al‐Huniti et al. · Clinical Pharmacology & Therapeutics · 2018 · 24 citations · Full text

Medicine, Pharmacology, Translational Sciences +17